Form 4: Atai Life Sciences: Apeiron Investment Group Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Apeiron Investment Group Ltd., a significant shareholder in ATAI Life Sciences N.V., reports changes in beneficial ownership related to convertible notes.
Summary
- Apeiron Investment Group Ltd. filed a Form 4 with the SEC on April 17, 2024, reporting changes in beneficial ownership of ATAI Life Sciences N.V. securities.
- The filing pertains to the exchange of convertible notes issued by ATAI Life Sciences AG for convertible notes issued by ATAI Life Sciences N.V. with substantially similar terms.
- The transaction involved 147,950 convertible notes, each with a notional principal amount of EUR 1.00 and a conversion price of EUR 17.00 per note.
- These notes are convertible into 2,367,200 common shares.
- Christian Angermayer, as the majority shareholder of Apeiron Investment Group Ltd., may be deemed to beneficially own the securities held by Apeiron.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting changes in beneficial ownership, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.
Stakeholder Impact
- Shareholders are informed about changes in ownership structure.
- The filing provides transparency regarding the holdings of major shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of transaction involving convertible notes. |
| 04/15/2024 | Date exercisable for convertible notes. |
| 09/30/2025 | Expiration date for convertible notes. |
| 04/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.